Evidence map›Paper›PMID 31170286›Full record

ArticleCarcinogenesis2020

Generation of focal mutations and large genomic deletions in the pancreas using inducible in vivo genome editing.

Amrendra Mishra, Fatemeh Emamgholi, Zulrahman Erlangga, Björn Hartleben, Kristian Unger, Katharina Wolff, Ulrike Teichmann, Michael Kessel, Norman Woller, Florian Kühnel and 6 more

Open access · greenAbstract read
In one paragraph

Article in Carcinogenesis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Ubiquitin signaling in pancreatic ductal adenocarcinoma.Frontiers in molecular biosciences · 2023
    Review
  3. Article
  4. Review
  5. Review
  6. WNT Ligand Dependencies in Pancreatic Cancer.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Amrendra MishraDepartment of Gastroenterology, Hepatology, and Endocrinology, Hannover, Germany.
Fatemeh EmamgholiDepartment of Gastroenterology, Hepatology, and Endocrinology, Hannover, Germany.
Zulrahman ErlanggaDepartment of Gastroenterology, Hepatology, and Endocrinology, Hannover, Germany.
Björn HartlebenDepartment of Pathology, Hannover Medical School, Hannover, Germany.
Kristian UngerResearch Unit Radiation Cytogenetics, German Research Center for Environmental Health, Munich, Germany.
Katharina WolffDepartment of Gastroenterology, Hepatology, and Endocrinology, Hannover, Germany.
Ulrike TeichmannAnimal House.
Michael KesselDepartment for Molecular Cell Biology, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany.
Norman WollerDepartment of Gastroenterology, Hepatology, and Endocrinology, Hannover, Germany.
Florian KühnelDepartment of Gastroenterology, Hepatology, and Endocrinology, Hannover, Germany.
Lukas E DowWeill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, USA.
Michael P MannsDepartment of Gastroenterology, Hepatology, and Endocrinology, Hannover, Germany.
Arndt VogelDepartment of Gastroenterology, Hepatology, and Endocrinology, Hannover, Germany.
Scott W LoweCancer Biology and Genetics Program, Sloan Kettering Institute, New York, USA.
Anna SaborowskiDepartment of Gastroenterology, Hepatology, and Endocrinology, Hannover, Germany.
Michael SaborowskiDepartment of Gastroenterology, Hepatology, and Endocrinology, Hannover, Germany.
Cornell University · USHelmholtz Zentrum München · DEKettering University · USMax Planck Institute for Biophysical Chemistry · DEMedizinische Hochschule Hannover · DE

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Beyond the nearly uniform presence of KRAS mutations, pancreatic cancer is increasingly recognized as a heterogeneous disease. Preclinical in vivo model systems exist, but with the advent of precision oncology, murine models with enhanced genetic flexibility are needed to functionally annotate genetic alterations found in the human malignancy. Here, we describe the generation of focal gene disruptions and large chromosomal deletions via inducible and pancreas-specific expression of Cas9 in adult mice. Experimental mice are derived on demand directly from genetically engineered embryonic stem cells, without the need for further intercrossing. To provide initial validation of our approach, we show that disruption of the E3 ubiquitin ligase Rnf43 accelerates KrasG12D-dependent tumourigenesis. Moreover, we demonstrate that this system can be used to rapidly interrogate the impact of complex cancer-associated alleles through the generation of a previously unstudied 1.2 megabase deletion surrounding the CDKN2A and CDKN2B tumour suppressors. Thus, our approach is capable of reproducibly generating biallelic and precise loss of large chromosomal fragments that, in conjunction with mutant Kras, leads to development of pancreatic ductal adenocarcinoma with full penetrance.

Indexed as

Gene EditingAnimalsCarcinogenesisCarcinoma, Pancreatic DuctalCell Line, TumorDisease Models, AnimalGenome, HumanHumansMiceMutationPancreasPancreatic NeoplasmsPrecision MedicineSequence Deletion

Identifiers

PMID31170286
PMCPMC8204487
OpenAlexW2951595587

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.